Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Drug sales expected to top $1.3T in 2018

August 4, 2015
Life sciences
Drug sales crossed a significant metric last year. They grew past $1 trillion. And for those industry insiders thinking global sales will taper off, a new report says think again. Expect sales to top $1.3 trillion in 2018.
 
Recent years have been full of reports about the falloff in pharma R&D and what that will mean to drug sales going forward, but there are promising signs in the last 12 months, according to the Thomson Reuters 2015 CMR International Pharmaceutical R&D Factbook. It points to the record 41 FDA new drug approvals in 2014, a 93% approval rate. There were actually 46 new drugs launched last year, which the report says was the highest number in more than a decade.
 
The growth will be powered by the fact that many of those new drugs are specialty and anticancer drugs, many with orphan designations, and many with eye-popping prices, a trend that continues. Think of Merck’s ($MRK) Keytruda and Bristol-Myers Squibb’s Opdivo. Of course the hep C drugs, Sovaldi and Harvoni, from Gilead Sciences played a significant role in rising drug spending last year, accounting for $12 billion themselves.
 
The megagrowth in drug sales in the U.S., the world’s single largest market, has already been noted. A recent report from IMS Institute for Healthcare Informatics found that U.S. drug spending alone was up more than $43 billion last year, a record increase. Spending on prescription drugs hit $374 billion in 2014, on a record-setting volume of 4.3 billion prescriptions filled. That translated into a 13% jump overall and 10% per capita, compared with an overall increase of 3.2% in 2013, the IMS Health report notes.
 
But while the portents are good for pharma in terms of worldwide growth, it is not to say everything looks great. About 95% of drug sales still came from established products that will eventually see their market share gobbled up by generics. Still, “This is an extraordinary year for pharma,” said Basil Moftah, president of Thomson Reuters IP & Science.
 
By Eric Palmer
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach